Jørn Frederik Falch

FCMB, based in Vejle, Denmark, is a molecular diagnostics company that develops a system for prenatal genetic analysis. FCMB is committed to developing new, no risk diagnostic method to assess genetic abnormalities, such as Down syndrome. Their team includes world-class scientists within the field of fetal cell research and experts in prenatal testing.

Cytoguide is a new biotech company devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. The company has the IP right for existing CD163 targeting technology as well as strong scientific experience and know-how to exploit the use of this receptor for drug therapy. The combined drugs are aimed to improve the treatment of monocyte/macrophage-related diseases including autoimmune disease, leukemia and infectious diseases.

Atherocheck ApS is a holding company that provides atherosclerosis research services. It designs and develops diagnostic test for the early diagnosis of patients at risk of developing atherosclerosis. The firm is categorized under other research and experimental development on natural sciences and engineering. The company was founded in 2006 and is headquartered in Aarhus, Denmark.

Curatio ApS develops devices for mechanical cleaning of wounds in emergency rooms. Its products are marketed under the brand names Curapulse, Curasafe, and Curagate. The company is headquartered in Nordborg, Denmark.

Part of Lundbeck Foundation, NeuronIcon ApS is a biotechnology manufacturing Danish company. The company is based in Aarhus, Denmark. NeuronIcon was acquired by H. Lundbeck A/S on July 07, 2009.

Østjysk Innovation A/S provides knowledge, skills, and administrative services. It also provides services in Biotechnology, medical technology and electronics. The company is headquartered in Aarhus, Denmark.

EnFutech ApS is a holding company that develops technologies for prevention, treatment, and eradication of Human Immunodeficiency Virus (HIV). Its platforms include both a new type of inhibitor that can be used as a prophylactic agent as well as a traditional drug for treatment of infection and a gene therapeutical approach to rendering the T-cells immune to HIV infection. The firm aims to combat infection, by developing effective anti-HIV treatments that can remove the virus both before and after it infects human cells. Its treatment is based on its novel technologies of blocking the HIV co-receptors using retargeted envelope proteins and receptor interference. The company was founded by Finn Skou Pedersen and Martin Tolstrup on August 23, 2007 and is headquartered in Aarhus, Denmark.

iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark.